✅ Model Answer:
• Diagnosis: Ataxia-telangiectasia (Louis-Bar syndrome) — ATM gene mutation causing progressive cerebellar ataxia, oculomotor apraxia (head thrusts), telangiectasias (conjunctival), IgA deficiency, elevated AFP, and cerebellar atrophy on MRI. Recurrent sinopulmonary infections due to immunodeficiency.
• Any other test: ATM genetic testing (confirmatory), immunoglobulin panel (IgG, IgM, IgE), lymphocyte subsets (T/B/NK cells), chromosomal breakage studies (radiosensitivity), chest CT (if recurrent infections), serum alpha-fetoprotein (AFP — already elevated).
• What to do next: Avoid radiation (X-rays, CT scans) due to cancer risk (radiosensitivity). Treat sinopulmonary infections aggressively (antibiotics). Consider IVIG if severe infections. Physiotherapy for ataxia. Speech/occupational therapy for dysarthria and oculomotor apraxia.
• Follow-up plan: Surveillance for malignancies (lymphoma, leukemia) — annual CBC. AFP monitoring (can rise with age). Genetic counseling for family. Prognosis: progressive neurologic decline; death usually from malignancy or respiratory failure in 20s-30s.

✅ Model Answer:
• Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder characterized by progressive cerebellar ataxia, oculomotor apraxia, telangiectasias, immunodeficiency, and increased cancer risk.
• Gene: ATM gene (Ataxia-Telangiectasia Mutated) located on chromosome 11q22.3.
• Protein: ATM protein is a serine/threonine protein kinase involved in DNA damage repair and cell cycle regulation (response to double-strand breaks).
• Mutation: Over 800 mutations identified (mostly truncating mutations).
• Prevalence: 1 in 40,000 to 1 in 100,000 live births.
• Inheritance: Autosomal recessive (both parents are carriers).
• Key features: Ataxia (early childhood), telangiectasias (conjunctival, skin), immunodeficiency (IgA deficiency), elevated AFP, cancer predisposition.

✅ Model Answer:
• Neurologic:
- Progressive cerebellar ataxia: Onset usually 1-4 years of age (gait ataxia, truncal ataxia).
- Oculomotor apraxia: Difficulty with voluntary eye movements (head thrusts to compensate).
- Dysarthria: Slurred, scanning speech.
- Choreoathetosis: Involuntary movements.
- Dystonia: Muscle spasms.
- Peripheral neuropathy: Sensory loss, areflexia (later stages).
• Telangiectasias:
- Conjunctival: Dilated blood vessels on the bulbar conjunctiva (often first appear by age 3-6).
- Cutaneous: Face, ears, antecubital/popliteal fossae (sun-exposed areas).
• Immunodeficiency:
- IgA deficiency: Most common (50-80%).
- IgG2 deficiency: May also occur.
- Recurrent sinopulmonary infections (bronchitis, pneumonia, sinusitis).
• Other:
- Elevated AFP: Alpha-fetoprotein is almost always elevated (useful diagnostic marker).
- Cerebellar atrophy: On MRI (progressive).
- Growth retardation: Failure to thrive.
- Premature aging: Skin changes, graying hair.

✅ Model Answer:
• AFP (Alpha-fetoprotein): A glycoprotein normally produced by the fetal liver and yolk sac.
• In AT: AFP is elevated in 80-95% of patients (usually >20 ng/mL).
• Mechanism: Liver dysfunction or production by other tissues due to ATM deficiency (exact mechanism unclear).
• Diagnostic utility:
- Elevated AFP + ataxia + telangiectasias = highly suggestive of AT.
- AFP levels are typically elevated in children >2 years (may be normal in infants).
- AFP increases with age (unlike hepatocellular carcinoma, where AFP is also elevated).
• Limitations: AFP can be elevated in other conditions (liver disease, some malignancies, normal infants).
• Follow-up: AFP levels are used as a tumor marker; a sudden significant rise may indicate malignancy.

✅ Model Answer:
• ATM protein: A key regulator of the DNA damage response (DDR) pathway — activates cell cycle checkpoints and DNA repair in response to double-strand breaks.
• Function: Phosphorylates p53, BRCA1, and other proteins involved in DNA repair and apoptosis.
• In AT: ATM deficiency leads to impaired DNA repair and increased sensitivity to ionizing radiation (X-rays, gamma rays).
• Clinical significance:
- Radiographs should be minimized or avoided entirely.
- CT scans should be avoided — use MRI or ultrasound when possible.
- Cancer risk: Increased risk of leukemia, lymphoma, and other malignancies (especially T-cell lymphomas).
- Radiation therapy: Contraindicated (can cause severe tissue damage and secondary malignancies).
- Chromosomal breakage studies: Can demonstrate increased chromosomal breakage after radiation exposure.

✅ Model Answer:
• Multidisciplinary care:
- Immunology: Monitor immunoglobulin levels, treat infections aggressively, consider IVIG if severe infections.
- Neurology: Physiotherapy for ataxia, occupational therapy, speech therapy for dysarthria.
- Ophthalmology: Monitor for telangiectasias and oculomotor apraxia.
- Oncology: Surveillance for malignancies (annual CBC, monitoring of AFP — sudden rise may indicate malignancy).
- Radiation avoidance: Minimize X-rays and CT scans; use MRI and ultrasound when possible.
- Respiratory: Pulmonary hygiene, treat infections promptly.
- Nutrition: Maintain adequate nutrition, manage swallowing difficulties.
• Pharmacological:
- No specific disease-modifying therapy available.
- Antioxidants: Vitamin E, vitamin C (limited evidence).
- Gene therapy: Under investigation.
• Genetic counseling: Autosomal recessive, 25% recurrence risk for siblings.

✅ Model Answer:
• Complications:
- Malignancies: Lymphoma (most common — especially T-cell), leukemia, breast cancer (in carriers), other solid tumors.
- Infections: Recurrent sinopulmonary infections (bronchiectasis, pneumonia, sinusitis) due to IgA deficiency and impaired immunity.
- Progressive neurological decline: Loss of ambulation (wheelchair by adolescence/early adulthood).
- Respiratory failure: Due to recurrent infections and bronchiectasis.
- Swallowing difficulties (dysphagia): Aspiration pneumonia.
- Growth failure: Poor weight gain, short stature.
- Premature aging: Skin changes, graying hair.
- Death: Usually from malignancy (lymphoma) or respiratory failure in 20s-30s.

✅ Model Answer:
• Prognosis:
- Poor: Progressive neurologic and immunologic decline.
- Life expectancy: Usually 20-30 years (most common cause of death: malignancy or respiratory failure).
- Wheelchair dependence: Usually by 10-15 years of age.
- Variable severity: Some patients have milder forms (variant AT) with slower progression.
• Long-term follow-up:
- Oncology: Annual surveillance for lymphoma/leukemia (physical exam, CBC, AFP monitoring).
- Pulmonary: Chest CT, pulmonary function tests (monitor for bronchiectasis).
- Immunology: Monitor immunoglobulin levels, consider IVIG if infections persist.
- Neurology: Physical therapy, mobility aids, occupational therapy.
- Psychosocial: Psychological support, education planning, family counseling.
- Genetic counseling: For family members (carrier testing, prenatal diagnosis).
- Palliative care: Early involvement for symptom management and quality of life.